Skip to NavigationSkip to content

Lundbeck and Otsuka's bipolar treatment fails Phase 3 trials due to unexpected placebo effect

Published on 15/02/19 at 09:43am

Lundbeck and Otsuka’s treatment for bipolar disorder, Rexulti, failed to achieve its primary endpoint in two separate Phase 3 trials.

Brexpiprazole (Rexulti) did not meet its primary endpoint in two three-week, double-blind, placebo-controlled Phase 3 trials as a treatment for patients with manic episodes associated with bipolar I disorder.

The two trials involved around 650 bipolar I patients who had experienced an acute manic episode that required hospitalisation.

The studied did not perform better than placebos as measured by the Young Mania Rating Scale (YMRS). In both studies placebo performed substantially higher than anticipated.

Brexpiprazole was generally well tolerated during trials. The failure of trials in bipolar I disorder do not have any bearing on brexpiprazole’s use a treatment for major depressive disorder (MDD) or schizophrenia.

Louis Goss

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches